Muramyl Tripeptide Plus Chemotherapy Reduces Metastasis in Non-Metastatic Osteosarcoma: A Single-Center Experience

BACKGROUND: The immunomodulator mifamurtide plus a chemotherapy regimen has been shown to significantly improve the outcome in non-metastatic osteosarcoma patients. We report the results of the addition of mifamurtide to chemotherapy in newly diagnosed patients with osteosarcoma. METHODS: A total of...

Descripción completa

Detalles Bibliográficos
Autores principales: Taçyıldız, Nurdan, Ünal, Emel, Dinçaslan, Handan, Çakmak, H Mine, Köse, Kenan, Tanyıldız, Gülşah, Kartal, Ömer
Formato: Online Artículo Texto
Lenguaje:English
Publicado: West Asia Organization for Cancer Prevention 2020
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7437342/
https://www.ncbi.nlm.nih.gov/pubmed/32212798
http://dx.doi.org/10.31557/APJCP.2020.21.3.715

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7437342/
https://www.ncbi.nlm.nih.gov/pubmed/32212798
http://dx.doi.org/10.31557/APJCP.2020.21.3.715

Ejemplares similares